Abstract
The survival rate of patients with colorectal cancer (CRC) is steadily increasing over the past decade. However, CRC continue to be one of the leading causes of cancer-related fatality in the United States. Current targeted strategies offer limited clinical benefits and the overall survival rate for CRC remains low. Improved understanding of the molecular changes associated with CRC that control growth factor signaling and evasion of cell death allow for the development of improved targeted therapy. This review aims to discuss some of the emerging therapies aimed to target CRC.
Keywords: Clinical, colorectal cancer, DPYD, RAS, targeted therapy, TRAIL.
Current Clinical Pharmacology
Title:Novel and Emerging Targeted Therapies of Colorectal Cancer
Volume: 10 Issue: 4
Author(s): Niklas Finnberg, Prashanth Gokare and Wafik S. El-Deiry
Affiliation:
Keywords: Clinical, colorectal cancer, DPYD, RAS, targeted therapy, TRAIL.
Abstract: The survival rate of patients with colorectal cancer (CRC) is steadily increasing over the past decade. However, CRC continue to be one of the leading causes of cancer-related fatality in the United States. Current targeted strategies offer limited clinical benefits and the overall survival rate for CRC remains low. Improved understanding of the molecular changes associated with CRC that control growth factor signaling and evasion of cell death allow for the development of improved targeted therapy. This review aims to discuss some of the emerging therapies aimed to target CRC.
Export Options
About this article
Cite this article as:
Finnberg Niklas, Gokare Prashanth and El-Deiry S. Wafik, Novel and Emerging Targeted Therapies of Colorectal Cancer, Current Clinical Pharmacology 2015; 10 (4) . https://dx.doi.org/10.2174/1574884710666151020095911
DOI https://dx.doi.org/10.2174/1574884710666151020095911 |
Print ISSN 1574-8847 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3938 |
Related Articles
-
Key Questions in Metastasis: New Insights in Molecular Pathways and Therapeutic Implications
Current Pharmaceutical Biotechnology SBRT for Liver Cancer
Current Cancer Therapy Reviews Alkaloid-Metal Based Anticancer Agents
Current Topics in Medicinal Chemistry Application of a Deep Matrix Factorization Model on Integrated Gene Expression Data
Current Bioinformatics Plant Polyphenols and Tumors: From Mechanisms to Therapies, Prevention, and Protection Against Toxicity of Anti-Cancer Treatments
Current Medicinal Chemistry IAPs as a Target for Anticancer Therapy
Current Cancer Drug Targets Proteomics in the Search for Biomarkers of Animal Cancer
Current Protein & Peptide Science Sulfotransferase 1A1 as a Biomarker for Susceptibility to Carcinogenesis: From Molecular Genetics to the Role of Dietary Flavonoids
Current Drug Metabolism Pharmaceutical Strategies Enhancing Cell Penetration Efficiencies of Non-Viral Gene Delivery Systems
Current Gene Therapy Intravitreal Anti-VEGF Drugs as Adjuvant Therapy in Diabetic Retinopathy Surgery
Current Diabetes Reviews Unveiling the Transient Protein-Protein Interactions that Regulate the Activity of Human Lemur Tyrosine Kinase-3 (LMTK3) Domain by Cyclin Dependent Kinase 5 (CDK5) in Breast Cancer: An in silico Study
Current Proteomics Importance of Pharmacist in Oxaliplatin Hepatotoxicity Associated with Inadequate Nutritional Diet: Case Report
Current Nutrition & Food Science Active-Targeted Nanotherapy Strategies for Prostate Cancer
Current Cancer Drug Targets Potentialities of Induced Pluripotent Stem (iPS) Cells for Treatment of Diseases
Current Molecular Medicine Can Untargeted Metabolomics Be Utilized in Drug Discovery/Development?
Current Topics in Medicinal Chemistry Past, Present and Future Strategies of Immunotherapy in Gynecological Malignancies
Current Molecular Medicine Modulation of Notch Signaling as a Therapeutic Approach for Liver Cancer
Current Gene Therapy Hsp90 Affecting Chromatin Remodeling Might Explain Transgenerational Epigenetic Inheritance in Drosophila
Current Genomics Chemotherapy and Target Therapy in the Management of Adult High- Grade Gliomas
Current Cancer Drug Targets Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway
Current Cancer Drug Targets